| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/24/2013 | WO2013010238A1 Microparticle pharmaceutical compositions containing antiparasitics for prolonged subcutaneous therapy, use of the pharmaceutical compositions for producing a medicament, and method for treating parasitoses |
| 01/24/2013 | WO2012166923A3 Drug loaded polymeric nanoparticles and methods of making and using same |
| 01/24/2013 | WO2012151252A3 Composition and method for treatment of diabetes |
| 01/24/2013 | WO2012149393A9 Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells |
| 01/24/2013 | WO2012142328A3 Polymer microsphere compositions for localized delivery of therapeutic agents |
| 01/24/2013 | WO2012099805A3 Nanoparticle based immunological stimulation |
| 01/24/2013 | WO2011159491A8 Controlled release levetiracetam formulations |
| 01/24/2013 | US20130023736 Systems for drug delivery and monitoring |
| 01/24/2013 | US20130023714 Medical and Imaging Nanoclusters |
| 01/24/2013 | US20130023688 Phosphorus-containing compounds with polymeric chains, and methods of making and using the same |
| 01/24/2013 | US20130023485 Parenteral formulations of peptides for the treatment of systematic lupus erythematosus |
| 01/24/2013 | US20130022685 Topical Compositions and Methods of Detection and Treatment |
| 01/24/2013 | US20130022684 Oral pharmaceutical composition comprising fenofibric acid and an alkalifying agent |
| 01/24/2013 | US20130022683 Method for improving dissolution of anticoagulant agent |
| 01/24/2013 | US20130022682 Ultra-Stable Oligonucleotide-Gold And-Silver Nanoparticle Conjugates And Method Of Their Preparation |
| 01/24/2013 | US20130022681 Granules for pharmaceutical preparations, methods and apparatus for their production |
| 01/24/2013 | US20130022680 Modalities for the treatment of degenerative diseases of the retina |
| 01/24/2013 | US20130022679 Controlled Release and Taste Masking Oral Pharmaceutical Composition |
| 01/24/2013 | US20130022678 Oral controlled release dosage form |
| 01/24/2013 | US20130022677 Delayed prolonged drug delivery |
| 01/24/2013 | US20130022676 Pulsatile drug release |
| 01/24/2013 | US20130022675 Drug delivery system |
| 01/24/2013 | US20130022674 Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| 01/24/2013 | US20130022673 Enhancement of magnesium uptake in mammals |
| 01/24/2013 | US20130022672 Stabilized Amorphous Forms of Imatinib Mesylate |
| 01/24/2013 | US20130022671 Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| 01/24/2013 | US20130022670 Aqueous Pharmaceutical Formulation of Tapentadol for Oral Administration |
| 01/24/2013 | US20130022669 Branched, compact polyethyleneglycol derivatives |
| 01/24/2013 | US20130022668 Biologically Active Taxane Analogs And Methods Of Treatment By Oral Administration |
| 01/24/2013 | US20130022667 Fidgetin-like 2 as a target to enhance wound healing |
| 01/24/2013 | US20130022666 Methods and compositions for transfer of mitochondria into mammalian cells |
| 01/24/2013 | US20130022665 Cationic lipids for therapeutic agent delivery formulations |
| 01/24/2013 | US20130022664 E.coli lpfa antigen for prevention and treatment of infectious diseases |
| 01/24/2013 | US20130022663 Method of making and using a topical medicated formula and delivery system to use to prevent and treat breast diseases and breast cancer as well as use as skin wellness and anti-wrinkle formula |
| 01/24/2013 | US20130022662 Compressed chewing gum tablet comprising taste-masking agent |
| 01/24/2013 | US20130022661 Bio-remodable bone augmentation device and method |
| 01/24/2013 | US20130022660 Drug delivery system for the prevention of cerebral vasospasm |
| 01/24/2013 | US20130022654 Controlled release pharmaceutical compositions of tapentadol |
| 01/24/2013 | US20130022653 Biomimetic hydroxyapatite synthesis |
| 01/24/2013 | US20130022652 Stable medicated chewing gum comprising cyclodextrin inclusion complex |
| 01/24/2013 | US20130022651 Hydrogel materials incorporating eluting ceragenin compound |
| 01/24/2013 | US20130022650 Compositions containing salmeterol, fluticasone and cromoglicic acid |
| 01/24/2013 | US20130022649 Snalp formulations containing antioxidants |
| 01/24/2013 | US20130022648 Granules of porous biocompatible materials |
| 01/24/2013 | US20130022647 Polymers for reversing heparin-based anticoagulation |
| 01/24/2013 | US20130022646 Controlled Release Formulations of Opioids |
| 01/24/2013 | US20130022645 Pharmaceutical formulations of bisphosphonate with enhanced oral bioavailability |
| 01/24/2013 | US20130022644 Novel n-phenylacetamide derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them |
| 01/24/2013 | US20130022643 Antimicrobial Anti-chafing Chelated Silver Oxide Compound |
| 01/24/2013 | US20130022636 Physical Mode of Action Pesticide |
| 01/24/2013 | US20130022551 DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
| 01/24/2013 | US20130022544 Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
| 01/24/2013 | CA2842654A1 Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis |
| 01/24/2013 | CA2842582A1 Water-based plaster |
| 01/24/2013 | CA2842550A1 Intravaginal devices for drug delivery |
| 01/24/2013 | CA2842306A1 Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers |
| 01/24/2013 | CA2842277A1 Topical oily foam formulations |
| 01/24/2013 | CA2842273A1 Patch containing diclofenac and thiocolchicoside |
| 01/24/2013 | CA2842175A1 Tablet containing dehydroepiandrosterone (dhea) |
| 01/24/2013 | CA2841969A1 Fixed dose combination of bimatoprost and brimonidine |
| 01/24/2013 | CA2841960A1 Novel compositions and methods for treating prostate cancer |
| 01/24/2013 | CA2841851A1 Composition and method for treating hpv |
| 01/24/2013 | CA2841358A1 Pharmaceutical compositions for rectal administration |
| 01/24/2013 | CA2840102A1 Formulation of transparent and nutritive microemulsions |
| 01/24/2013 | CA2838793A1 Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides |
| 01/24/2013 | CA2833280A1 Microwave vacuum-drying of organic materials |
| 01/23/2013 | EP2548894A1 Pharmaceutical compositions with enhanced performance |
| 01/23/2013 | EP2548638A2 A method for producing polymer-encapsulated nanoparticles |
| 01/23/2013 | EP2548608A1 Proteoglycan-containing microneedle array |
| 01/23/2013 | EP2548581A2 A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
| 01/23/2013 | EP2548566A1 Composition for transnasal administration and method for producing same |
| 01/23/2013 | EP2548556A1 Method for improving dissolvability of anticoagulant |
| 01/23/2013 | EP2548553A1 Galenical formulations of aliskiren |
| 01/23/2013 | EP2548552A2 Titration package for 1-amino-alkylcylohexanes |
| 01/23/2013 | EP2548551A1 Patch preparation |
| 01/23/2013 | EP2548550A1 Emulsion-based micro particles |
| 01/23/2013 | EP2548456A1 Emulsions including a PEG-derivative of tocopherol |
| 01/23/2013 | EP2548441A1 Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate |
| 01/23/2013 | EP2547765A1 Beta-propiolactone for inactivation of viruses in pharmaceutical pancreatic enzyme preparations |
| 01/23/2013 | EP2547436A2 Melt emulsification |
| 01/23/2013 | EP2547370A1 Universal cell-directed theranostics |
| 01/23/2013 | EP2547369A1 A nanoparticle comprising a micelle formed by an amphiphilic block- copolymer and encapsulating a gadolinium complex |
| 01/23/2013 | EP2547351A1 Pharmaceutical compositions of growth hormone secretagogue receptor ligands |
| 01/23/2013 | EP2547340A2 Ophthalmic formulations of cetirizine and methods of use |
| 01/23/2013 | EP2547335A2 Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport |
| 01/23/2013 | EP2547333A2 Stable bortezomib formulations |
| 01/23/2013 | EP2547332A1 Heterogeneous implantable devices for drug delivery |
| 01/23/2013 | EP2547331A1 Gastro-resistant enzyme pharmaceutical compositions |
| 01/23/2013 | EP2547330A2 Orally disintegrating tablet formulations of donepezil and process for preparing the same |
| 01/23/2013 | EP2547329A1 Theranostic delivery systems with modified surfaces |
| 01/23/2013 | EP2547328A2 Ccr7 ligand delivery and co-delivery in immunotherapy |
| 01/23/2013 | EP2547327A2 Lipid vesicle compositions and methods of use |
| 01/23/2013 | EP2547325A2 Spray-pumpable composition suitable for topical skin application |
| 01/23/2013 | EP2547324A2 Process of manufacturing a lyophilized fast dissolving, muti-phasic dosage form |
| 01/23/2013 | EP2547323A2 Pharmaceutical composition for treatment of increased intraocular pressure |
| 01/23/2013 | EP2547322A2 Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns |
| 01/23/2013 | EP2547206A1 Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic |
| 01/23/2013 | EP2158900B1 Polymeric delivery formulations of leuprolide with improved efficacy |
| 01/23/2013 | CN202682391U Poultice patch for treating pain at necks, shoulders, waists and legs |
| 01/23/2013 | CN202682390U Traditional Chinese medicine external application paste capable of quickly relieving pain and itch |